Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Local residents of Zagazig district Willing to participate in the study and give a written consent. Exclusion Criteria: Subjects who took influenza vaccine, cortisone, or any other immunosuppressive agents such as radiation or chemotherapy.
Diagnosed with infections or malignancies Presence of auto-immune disorders Marked portal hypertension, pancytopenia, renal, or kidney failure Presence of major psychological insult or under medication for psychological insult. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. More Information. Exp Ther Med. Epub Jan 8. Qual Life Res. Epub Sep 5. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. To treat cancer A small study suggests MGN-3 may improve response to standard therapies in liver cancer patients. However, there is no evidence that it can be used as a treatment alone, and larger studies are needed. To prevent and treat chemotherapy side effects MGN-3 reduced the side effects of standard therapies in liver cancer patients, but additional studies confirming such effects are needed.
To stimulate the immune system MGN-3 stimulated immune cells in lab studies and small studies of cancer patients, but additional studies are needed. To treat chronic fatigue syndrome A clinical study did not find MGN-3 effective in treating chronic fatigue syndrome.
Side Effects. No side effects have been reported. For Healthcare Professionals. Brand Name. Clinical Summary. Food Sources. Rice, mushrooms. Mechanism of Action. Adverse Reactions. None reported. Herb-Drug Interactions. Herb Lab Interactions. Arabinoxylan rice bran MGN-3 enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial.
Anticancer Res. Ghoneum MH, Maeda H. Immunopotentiator and method of manufacturing the same Arabinoxylane Compound. Patent Filed July 12, Ghoneum M, Jewett A.
Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Rats receiving MGN-3 were healthier; gained weight and had a lower incidence of diarrhea and gross intestinal pathology compared with control.
Endo and Kanbayashi MGN-3 both orally and IP showed accelerated protection against severe loss of body weight of mice due to cisplatin. The result was statistically significant. Badr El-Din et al MGN-3 dissolved in 0. MGN-3 significantly delayed growth in both tumor volume No adverse side effects due to MGN-3 treatment were observed. Noaman et al Female Swiss albino mice inoculated with EAC cells, bearing solid tumors. MGN-3 suppressed the growth of tumors; normalized lipid peroxidation level, augmented glutathione contents, and enhanced antioxidant enzymes activity in blood, liver, and tumor tissue.
More pronounced effects were observed when treated by MGN-3 as early as day 4. NK cells fresh or MGN-3 activated. NK cellular IV therapy began 7 days after tumor cells inoculation, twice a week for 4 wk. MGN-3 stimulated NK cells inhibited neuroblastoma growth and increased survival compared with control. The results were statistically significant. MGN-3 significantly lowered incidence of dysplasia and gastric cancer when combined with MNNG; effects observed include suppression of Ki tumor marker, upregulation of apoptotic gastric cancer cells via mitochondrial-dependent pathway, and protection against decrease in lymphocyte levels.
Inhibition of tumor growth was associated with reduced cancer cell proliferation, increased DNA damage and apoptosis. Badr El-Din et al 41 —Abstract only.
Ghoneum and Brown White blood cells WBCs count at 5. WBCs count at Condition stable for 4 y at the point of reporting. Prostate-specific antigen PSA level at 0. PSA level remained within normal range for 4 y at the point of reporting.
NK cell activity increased 2-fold from baseline No evidence of recurrence seen in computed tomography CT scans or biopsies. Kawai Patient survived 2 y and 2 mo since detection typical survival time: 2 wk to 11 mo and was still alive at the time of reporting.
MGN-3 helped to prolong life and improved quality of life. Kaketani Initial prognosis was 3 mo of life. Patient survived 17 mo with a normal life and died of hematemesis not related to cancer.
Okamura Initially pronounced to have 1 mo to live. Patient entered 7th year of treatment at the time of reporting living a normal working life and received treatment on outpatient basis. Conventional treatment at 2 other medical institutions previously IV infusion of BRP once every 4 wk. Liver cancer marker and immunocompetence improved after 6 mo. Liver function markers raised initially and decreased at 1 y, with jaundice disappeared, appetite improved, no pain occurred through to 1 y 11 mo of treatment.
Hepatic tumor markers decreased after 6 mo of treatment. Clinical symptoms improved and jaundice disappeared. Lung tumor maker tissue polypeptide antigeny [TPA] decreased after 4 mo. Immunocompetence TK activity gradually improved. Liver function glutamic-pyruvic transaminase [GPT] improved rapidly and immunocompetence TK activity stabilized after 1 mo of treatment.
Patient continued to work with no subjective symptoms at the time of reporting. Markus et al Metastatic hemangiopericytoma of the skin with multiple pulmonary nodules. Wide local excision for removal of the skin lesion Patient refused further conventional treatment for pulmonary nodules.
Lung masses steadily decreased in size by serial imaging and became undetectable after 34 mo of MGN-3 therapy. Hajto et al Left ovary sarcoma and endometrium sarcoma with a metastasis in the right ovary. At the time of reporting, the patient was tumor-free after 5 y.
After a treatment for 7 mo, a nearly complete remission CR of the primary tumor and CR of all metastases was established. Follow-up results of 4 patients were reported. Tsunekawa Body height and weight, leukocyte count and subsets, NK cell activity, tumor markers, adverse reactions, and interruptions. No subjective or objective adverse effects. Improvement in leukocyte count and subsets, increased and normalized NK cell activity after treatment.
Lissoni et al Non—statistically significant increase in the mean number of Th cells and decrease in Treg cell. Golombick et al Conventional oncologic therapy 0. Quality of life questionnaire pain, anxiety, physical activity, appetite, sleep, digestion, side effect, self-perceived improvement.
Improvement of physical activity and decrease of side effects during conventional oncotherapy. Takahara and Sano NK cells activity, survival rate; custom quality of life scoring on pain, malaise, nausea, and appetite. MGN-3 group achieved higher survival rate and better appetite than control group. Bang et al MGN-3 group showed lower recurrence, higher survival after 2nd year, and significantly lower AFP change compared with control.
Cholujova et al Alternating courses of chemotherapy: alkylating agents, anthracyclines, and glucocorticoids. Masood et al Chemotherapy induced side effects tiredness, anorexia, vomiting, and hair loss. MGN-3 group experienced significant reduction in tiredness; increased appetite; no antiemetic needs; and less hair fall compared with control group.
Itoh et al Radiation therapy: combination of external-beam radiation therapy and brachytherapy Chemotherapy: cisplatin and 5-fluorouracil. Gastrointestinal side effects of chemoradiotherapy diarrhea, nausea, vomiting, loss of appetite, safety ; WBC count; NK cell activity. In using this website you agree that neither Memorial Sloan Kettering nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented at this website.
This will help them manage your care and keep you safe. MGN-3 is a complex sugar derived from rice bran treated with extracts from three mushrooms: Shiitake , Coriolus versicolor , and Suehirotake.
The manufacturer claims that it stimulates several aspects of the immune system, causing overall immune stimulation. Lab studies suggest that MGN-3 can cause cell death in some cancer cells and increase their susceptibility to chemotherapy drugs.
Only a few short-term studies have been conducted in humans. Preliminary data suggest it may improve response and reduce side effects of standard therapies in liver cancer patients, but larger studies are needed to confirm these observations. MGN-3 is a proprietary product derived from rice bran treated with extracts from three mushrooms: shiitake Lentinus edodes , kawaratake Coriolus versicolor , and suehirotake Schizophyllum commune.
In vitro and animal studies suggest MGN-3 might be useful in mounting immune responses against infections and cancer 15 , facilitate apoptosis of human T-cell leukemia cells 6 , and protect against weight loss induced by cisplatin 8 and radiation Other preclinical models suggest it may act as a chemosensitizer 7 10 16 17 and radiosensitizer 18 , and exert cytotoxic 19 and chemopreventive 20 effects.
A few small short-term studies of MGN-3 have been conducted in humans. Some suggest improvements in irritable bowel symptoms 21 , health-related quality of life in older adults 22 and reduced viral load in patients with chronic hepatitis C In small studies of cancer patients, MGN-3 increased overall response and reduced adverse effects of standard therapies 1 , and improved immunomodulatory function 5 Other preliminary studies suggest possible benefit with rice bran arabinoxylan in combination with curcumin for patients with early-stage blood cancers MGN-3 is an arabinoxylan from rice bran made using enzymes from mycelia of shiitake, kawaratake, and suehirotake mushrooms.
The bioactive constituents are thought to be polysaccharides, which modulate TNF-alpha and IFN-gamma secretion, and augment NK cell function in vitro 3.
In rat models, MGN-3 exerted protective effects against liver injury by reducing expression of IL MGN-3 displayed synergistic effects with paclitaxel by causing DNA damage, enhancing apoptosis, and inhibiting cell proliferation in murine breast cancer cells In another study, MGN-3 exerted antioxidative activity and protected against radiation-induced loss of body and organ weight in mice In a study of myeloma patients, MGN-3 increased NK cell activity, the number of myeloid dendritic cells in peripheral blood, and concentrations of T helper cell type 1-related cytokines MGN-3 reduces alpha-fetoprotein levels in hepatocellular carcinoma patients undergoing standard therapies 1.
Skip to main content Important Update to Visitor Policy. Developing Your Personal Care Plan. Integrative Medicine at Home Membership Program. About Mind-Body Therapies.
0コメント